A Johnson & Johnson gene therapy in development for an inherited vision-loss disorder has failed a Phase 3 study, the latest clinical research setback for a rare eye disease that so far has no ...
Diseases that affect the retina, the light-sensitive layer at the back of the eye, are a significant cause of visual impairment and blindness. Gene therapy holds promise for treating some of these ...
ER-100 is being tested to restore vision by resetting the biological age of eye cells through epigenetic reprogramming, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results